Business Context and Reporting Period
This Form 6-K filing by InflaRx N.V. covers the month of June 2025, with the report dated June 27, 2025. The filing primarily addresses a change in the Company's independent registered public accounting firm.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates regarding the external auditor.
Material Changes
On June 26, 2025, InflaRx N.V. executed an engagement letter with KPMG AG Wirtschaftsprüfungsgesellschaft ("KPMG") to serve as its independent registered public accounting firm for the fiscal year ended December 31, 2025. Consequently, the Company ceased its engagement with EY GmbH & Co. KG Wirtschaftsprüfungsgesellschaft ("EY"), which had served as the auditor since the fiscal year ended December 31, 2020.
Guidance, Outlook, and Risks
- Reason for Change: The auditor change follows a shareholder vote at the Annual General Meeting on April 24, 2025, approving KPMG Accountants N.V. for the statutory annual accounts audit.
- Disagreements: The Company explicitly states the decision was not due to any disagreement with EY.
- Previous Audit Quality: EY did not resign or decline re-election. Their reports for the years ended December 31, 2024, and 2023, including internal control over financial reporting, were unqualified and contained no adverse opinions or disclaimers.
- Future Disclosures: Additional disclosures regarding the predecessor auditor will be included in the Form 20-F for the fiscal year ending December 31, 2025.
Key Facts for Investor Verification
- Confirm the effective date of the new audit engagement with KPMG (June 26, 2025).
- Verify the shareholder approval date for the auditor change (April 24, 2025).
- Review the upcoming Form 20-F for the fiscal year ending December 31, 2025, for detailed disclosures regarding the predecessor auditor (EY).
- Note that no financial disagreements or audit qualifications were reported for the periods audited by EY.